Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 84Lymphoma, Non-Hodgkin 71Lymphoma 62Lymphoma, Follicular 58Lymphoma, Mantle-Cell 57Lymphoma, Large B-Cell, Diffuse 40Multiple Myeloma 36Hodgkin Disease 30Lymphoma, B-Cell, Marginal Zone 28Recurrence 27Lymphoma, B-Cell 19Leukemia 18Waldenstrom Macroglobulinemia 14Neoplasms 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Neoplasms, Plasma Cell 8Lymphoma, T-Cell 7Leukemia, Myeloid, Acute 7Burkitt Lymphoma 7Lymphoma, T-Cell, Peripheral 6Leukemia, B-Cell 6Hematologic Neoplasms 6Sezary Syndrome 5Myelodysplastic Syndromes 5Mycosis Fungoides 5Immune System Diseases 5Small Cell Lung Carcinoma 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large-Cell, Anaplastic 4

Interventions

Paclitaxel 7Oxaliplatin 6Vincristine 4Radiotherapy 4Leucovorin 4Carboplatin 4Amifostine 4Taxes 3Sodium Chloride 3Procarbazine 3Methotrexate 3Fluorouracil 3Cytarabine 3xaliproden 2glucarpidase 2Rituximab 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Prednisolone 2Magnesium Sulfate 2Duloxetine Hydrochloride 2Dexamethasone 2Cyclophosphamide 2Cisplatin 2Calcium Gluconate 2Acupuncture Therapy 2neurotropin 1motexafin gadolinium 1haloperidol decanoate 1glutamic acid diethyl ester 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neurotoxicity Syndromes × Bendamustine Hydrochloride × Clear all
NCT03696784 2025-12-08

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

UNC Lineberger Comprehensive Cancer Center

Phase 1 Active not recruiting
19 enrolled
Lymphoid

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡